Superdrugs for superbugs

A new round of dangerous staph infections has biotechs scrambling for new antibiotics that could lead the market.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all RSS FEEDS (close)
By Aaron Smith, staff writer

More healthcare news...

NEW YORK ( -- Smaller biotechnology companies are ready to take the lead away from big pharma in developing antibiotics that can take on a new generation of deadly "superbugs."

The most common bug is methicillin-resistant Staphylococcus aureus, or MRSA, which is transferred through skin contact. Most infections occur in hospitals among patients with weakened immune systems. But staph is appearing in more public spaces, including schools.

Big pharmaceutical companies already dominate the skin-infection antibiotic market with drugs like Pfizer's (PFE, Fortune 500) blockbuster Zyvox and Wyeth's (WYE, Fortune 500) Tygacil. But their payoff doesn't appear to be big enough.

"Antibiotics were considered an area that you couldn't make a lot of money in," said Rachel McMinn, an analyst for Cowen and Co., "so Big Pharma made the decision to get out, and biotechs filled that gap," with a pipeline of new treatments. If their products get government approval, she said, they could lead to a multibillion-dollar market.

Oritavancin, an antibiotic for skin infections including MRSA, is awaiting decision from the Food and Drug Administration. Its maker, the biotech Targanta Therapeutics (TARG), submitted its approval application on Feb. 11, and the review could be completed this year.

Cethromycin from Advanced Life Sciences (ADLS) finished late-stage studies and is on track for FDA submission. The antibiotic has been studied as a guard against pneumonia, but Chief executive Michael Flavin said it could possibly be used for staph infections.

Faropenem, from Replidyne (RDYN), is in early-stage tests for MRSA. An antibiotic from privately held Paratek Pharmaceuticals is in early-stage tests for community and hospital infections. And Cubist's (CBST) fast-growing antibiotic Cubicin, which is already on the market, is being tested for a variety of other infections.

McMinn said the next action from the FDA will probably happen on Feb. 27, when an advisory panel votes on whether to support the approval of telavancin, an experimental MRSA antibiotic from Theravance (THRX).

Nearly 19,000 Americans died from MRSA infections in 2005, according to the Journal of the American Medical Association, surpassing the death rate from AIDS. This is just a fraction of the total number of infections, which are mostly minor.

Some of the most high-profile deaths occurred last year, when the drug-resistant strain killed a 17-year-old high school student in Virginia and a 12-year-old student in New York. This year, two members of a high school wrestling team in Nebraska became infected with the staph strain, exasperating concerns about in-school infections and contact sports.

"Drug resistance is on the rise and old drugs are working less well," said Jason Kantor, analyst for RBC Capital Markets. "MRSA is the big driver currently." To top of page

Photo Galleries
10 things you'll love about Windows 10 There's a lot to like about Windows 10. Here are our favorite features in Microsoft's soon-to-be-released operating system. More
Warren Buffett's gone cold. How his top 10 stocks are doing The Oracle of Omaha is an investing legend. But several of Berkshire Hathaway's biggest investments are off to a lousy start in 2015. Will shareholders complain at the annual meeting in Omaha on Saturday? More
BMW's M235i doesn't compromise BMW's new M235i gives you the performance of an M car for a lot less money. More